$ 0.75
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Decent dividends
Data is available to registered users only
Data is available to registered users only
About
Niox Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis and management of asthma. It offers NIOX VERO, a non-invasive point-of-care system that provides fractional exhaled nitric oxide (FeNO) measurements. The company was founded by Steven Harris and Charles Stuart Webb Swingland on May 19, 2006 and is headquartered in Oxford, the United Kingdom.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair
Data is available to registered users only